在最新的发展中，Genentech宣布其终止疾病药物Columbvi的标签扩大申请收到美国食品药品监督管理局（FDA）的拒绝。该公司最初希望将Columbvi与化疗结合，用于无法接受细胞移植的复发或灾难性治疗大B细胞瘤（DLBCC）患者。然而，FDA在回复信中指出，支持此申请的STARGLO研究未来提供足够的证据来支持这一早期治疗用途。目前，Columbvi仍然可以根据加速批准用于已经接受过两次治疗的第三线或更后期的DLBCC患者。In this paper，we study the relationship between the mechanism and the relationship between the mechanism. In addition，Columbi has been approved for reproductive or resistant DLBCL patients in global 60 more countries. In this paper，we discuss the relationship between the mechanism and the relationship between mechanism.